AKT1 and esophageal squamous cell carcinoma: HMGB2 depletion enhances NK cell cytotoxicity via the ANGPT1/PI3K/AKT pathway, suggesting its potential as a therapeutic target to improve NK cell-based immunotherapy in ESCC.